Analyst Marie Thibault of BTIG maintained a Buy rating on Boston Scientific, retaining the price target of $110.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Marie Thibault’s rating is based on Boston Scientific’s strong clinical and commercial outlook for its Watchman left atrial appendage closure franchise, reinforced by new CHAMPION-AF and HI-PEITHO data that both met primary endpoints and were published in NEJM. She believes these results, alongside management’s reiterated expectation for roughly 20% long-term global growth in LAAC, support Watchman’s evolution toward a first-line option versus NOACs for eligible atrial fibrillation patients.
She also expects the CHAMPION-AF data to underpin an FDA label expansion and subsequent efforts to secure broader CMS reimbursement, which could significantly enlarge the addressable market. While she acknowledges ongoing debate over stroke outcomes and trial design, her valuation framework—a $110 price target based on 28x her 12–24 month EPS estimate—reflects confidence that label, guideline, and coverage enhancements will drive meaningful upside in procedure volumes and earnings.
Thibault covers the Healthcare sector, focusing on stocks such as Boston Scientific, Ceribell, Inc., and Edwards Lifesciences. According to TipRanks, Thibault has an average return of -14.5% and a 31.59% success rate on recommended stocks.
In another report released today, Needham also reiterated a Buy rating on the stock with a $97.00 price target.